Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma

NCT05048810 is registered in ClinicalTrials.gov with Nanjing First Hospital, Nanjing Medical University as lead sponsor.

NCT NCT05048810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05048810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma
Lead sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Not applicable
Overall status
Completed
Start date
February 7, 2020
Completion date
March 1, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma